Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)

• Status: Completed
• Trial end date: 2012-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• Male and female outpatients, of age 18 - 54 years

• Patients diagnosed with stage 1 or stage 2 essential hypertension

• Normal physical examination findings and electrocardiogram (ECG) results or abnormal findings judged by the Investigator to be not clinically significant

Exclusion Criteria:

• Secondary hypertension or severe hypertension

• History of Type 1 diabetes mellitus

• A medical contraindication to discontinuing a current antihypertensive therapy

• Clinically significant respiratory disease that prohibit use of a beta blocker